2-deoxyglucose and beta-hydroxybutyrate

Metabolic agents for seizure control

Research output: Contribution to journalReview article

Abstract

Current anti-seizure drugs (ASDs) are believed to reduce neuronal excitability through modulation of ion channels and transporters that regulate excitability at the synaptic level. While most patients with epilepsy respond to ASDs, many remain refractory to medical treatment but respond favorably to a high-fat, low-carbohydrate metabolismbased therapy known as the ketogenic diet (KD). The clinical effectiveness of the KD has increasingly underscored the thesis that metabolic factors also play a crucial role in the dampening neuronal hyperexcitability that is a hallmark feature of epilepsy. This notion is further amplified by the clinical utility of other related metabolism-based diets such as the modified Atkins diet and the low-glycemic index treatment (LGIT). Traditional highfat diets are characterized by enhanced fatty acid oxidation (which produces ketone bodies such as beta-hydroxybutyrate) and a reduction in glycolytic flux, whereas the LGIT is predicated mainly on the latter observation of reduced blood glucose levels. As dietary implementation is not without challenges regarding clinical administration and patient compliance, there is an inherent desire and need to determine whether specific metabolic substrates and/or enzymes might afford similar clinical benefits, hence validating the concept of a “diet in a pill.” Here, we discuss the evidence for one glycolytic inhibitor, 2-deoxyglucose (2DG) and one metabolic substrate, b-hydroxybutyrate (BHB) exerting direct effects on neuronal excitability, highlight their mechanistic differences, and provide the strengthening scientific rationale for their individual or possibly combined use in the clinical arena of seizure management.

Original languageEnglish (US)
Article number172
JournalFrontiers in Cellular Neuroscience
Volume13
DOIs
StatePublished - Apr 12 2019

Fingerprint

3-Hydroxybutyric Acid
Deoxyglucose
Seizures
Ketogenic Diet
Glycemic Index
Diet
Epilepsy
Carbohydrate-Restricted Diet
Hydroxybutyrates
Ketone Bodies
Therapeutics
Patient Compliance
Ion Channels
Pharmaceutical Preparations
Blood Glucose
Fatty Acids
Fats
Carbohydrates
Observation
Enzymes

Keywords

  • 2-deoxyglucose (2DG)
  • Beta-hydroxybutyrate
  • Epilepsy
  • Glycolysis
  • Ketogenic diet
  • Ketone body
  • Ketosis
  • Metabolic therapy

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

2-deoxyglucose and beta-hydroxybutyrate : Metabolic agents for seizure control. / Rho, Jong M.; Shao, Lirong; Stafstrom, Carl.

In: Frontiers in Cellular Neuroscience, Vol. 13, 172, 12.04.2019.

Research output: Contribution to journalReview article

@article{a6e10a732e0e47c2b5fa1a183dd2dd7e,
title = "2-deoxyglucose and beta-hydroxybutyrate: Metabolic agents for seizure control",
abstract = "Current anti-seizure drugs (ASDs) are believed to reduce neuronal excitability through modulation of ion channels and transporters that regulate excitability at the synaptic level. While most patients with epilepsy respond to ASDs, many remain refractory to medical treatment but respond favorably to a high-fat, low-carbohydrate metabolismbased therapy known as the ketogenic diet (KD). The clinical effectiveness of the KD has increasingly underscored the thesis that metabolic factors also play a crucial role in the dampening neuronal hyperexcitability that is a hallmark feature of epilepsy. This notion is further amplified by the clinical utility of other related metabolism-based diets such as the modified Atkins diet and the low-glycemic index treatment (LGIT). Traditional highfat diets are characterized by enhanced fatty acid oxidation (which produces ketone bodies such as beta-hydroxybutyrate) and a reduction in glycolytic flux, whereas the LGIT is predicated mainly on the latter observation of reduced blood glucose levels. As dietary implementation is not without challenges regarding clinical administration and patient compliance, there is an inherent desire and need to determine whether specific metabolic substrates and/or enzymes might afford similar clinical benefits, hence validating the concept of a “diet in a pill.” Here, we discuss the evidence for one glycolytic inhibitor, 2-deoxyglucose (2DG) and one metabolic substrate, b-hydroxybutyrate (BHB) exerting direct effects on neuronal excitability, highlight their mechanistic differences, and provide the strengthening scientific rationale for their individual or possibly combined use in the clinical arena of seizure management.",
keywords = "2-deoxyglucose (2DG), Beta-hydroxybutyrate, Epilepsy, Glycolysis, Ketogenic diet, Ketone body, Ketosis, Metabolic therapy",
author = "Rho, {Jong M.} and Lirong Shao and Carl Stafstrom",
year = "2019",
month = "4",
day = "12",
doi = "10.3389/fncel.2019.00172",
language = "English (US)",
volume = "13",
journal = "Frontiers in Cellular Neuroscience",
issn = "1662-5102",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - 2-deoxyglucose and beta-hydroxybutyrate

T2 - Metabolic agents for seizure control

AU - Rho, Jong M.

AU - Shao, Lirong

AU - Stafstrom, Carl

PY - 2019/4/12

Y1 - 2019/4/12

N2 - Current anti-seizure drugs (ASDs) are believed to reduce neuronal excitability through modulation of ion channels and transporters that regulate excitability at the synaptic level. While most patients with epilepsy respond to ASDs, many remain refractory to medical treatment but respond favorably to a high-fat, low-carbohydrate metabolismbased therapy known as the ketogenic diet (KD). The clinical effectiveness of the KD has increasingly underscored the thesis that metabolic factors also play a crucial role in the dampening neuronal hyperexcitability that is a hallmark feature of epilepsy. This notion is further amplified by the clinical utility of other related metabolism-based diets such as the modified Atkins diet and the low-glycemic index treatment (LGIT). Traditional highfat diets are characterized by enhanced fatty acid oxidation (which produces ketone bodies such as beta-hydroxybutyrate) and a reduction in glycolytic flux, whereas the LGIT is predicated mainly on the latter observation of reduced blood glucose levels. As dietary implementation is not without challenges regarding clinical administration and patient compliance, there is an inherent desire and need to determine whether specific metabolic substrates and/or enzymes might afford similar clinical benefits, hence validating the concept of a “diet in a pill.” Here, we discuss the evidence for one glycolytic inhibitor, 2-deoxyglucose (2DG) and one metabolic substrate, b-hydroxybutyrate (BHB) exerting direct effects on neuronal excitability, highlight their mechanistic differences, and provide the strengthening scientific rationale for their individual or possibly combined use in the clinical arena of seizure management.

AB - Current anti-seizure drugs (ASDs) are believed to reduce neuronal excitability through modulation of ion channels and transporters that regulate excitability at the synaptic level. While most patients with epilepsy respond to ASDs, many remain refractory to medical treatment but respond favorably to a high-fat, low-carbohydrate metabolismbased therapy known as the ketogenic diet (KD). The clinical effectiveness of the KD has increasingly underscored the thesis that metabolic factors also play a crucial role in the dampening neuronal hyperexcitability that is a hallmark feature of epilepsy. This notion is further amplified by the clinical utility of other related metabolism-based diets such as the modified Atkins diet and the low-glycemic index treatment (LGIT). Traditional highfat diets are characterized by enhanced fatty acid oxidation (which produces ketone bodies such as beta-hydroxybutyrate) and a reduction in glycolytic flux, whereas the LGIT is predicated mainly on the latter observation of reduced blood glucose levels. As dietary implementation is not without challenges regarding clinical administration and patient compliance, there is an inherent desire and need to determine whether specific metabolic substrates and/or enzymes might afford similar clinical benefits, hence validating the concept of a “diet in a pill.” Here, we discuss the evidence for one glycolytic inhibitor, 2-deoxyglucose (2DG) and one metabolic substrate, b-hydroxybutyrate (BHB) exerting direct effects on neuronal excitability, highlight their mechanistic differences, and provide the strengthening scientific rationale for their individual or possibly combined use in the clinical arena of seizure management.

KW - 2-deoxyglucose (2DG)

KW - Beta-hydroxybutyrate

KW - Epilepsy

KW - Glycolysis

KW - Ketogenic diet

KW - Ketone body

KW - Ketosis

KW - Metabolic therapy

UR - http://www.scopus.com/inward/record.url?scp=85066933006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066933006&partnerID=8YFLogxK

U2 - 10.3389/fncel.2019.00172

DO - 10.3389/fncel.2019.00172

M3 - Review article

VL - 13

JO - Frontiers in Cellular Neuroscience

JF - Frontiers in Cellular Neuroscience

SN - 1662-5102

M1 - 172

ER -